|
A more recent version of this article appeared on May 1, 2003
Papers In Press, published online ahead of print March 16, 2003
J. Lipid Res., doi:10.1194/jlr.R300002-JLR200
Submitted on January 17, 2003
Revised on February 28, 2003
Accepted on March 4, 2003
Familial hypobetalipoproteinemia: a review
Gustav Schonfeld
Atherosclerosis, Nutrition and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110
Corresponding Author: gschonfe{at}im.wustl.edu
Abstract We review the genetics and pathophysiology of familial hypobetalipoproteinemia [FHBL], a mildly symptomatic genetically heterogeneous autosomal trait. The minority of human FHBL is caused by truncation-specifying mutations of the APOB gene on chromosome 2. In seven families linkage to chromosome 2 is absent, instead linkage is to chromosome 3 [3p21]. In others linkage is absent to both APOB and to 3p21. ApoB100 levels are ~25% of normal, instead of the 50% expected based on the presence of one normal allele, due to reduced rates of production. The presence of the truncating mutation seems to have a "dominant recessive" effect on apoB100 secretion. Concentrations of apoB truncations in plasma differ by truncation, but average at ~10% of normal levels. Lipoproteins bearing truncated forms of apoB are cleared more rapidly than apoB100 particles. In contrast with apoB100 particles cleared primarily in liver via the LDL receptor, most apoB truncation particles are cleared in renal proximal tubular cells via megalin. Since apoB defects cause a dysfunctional VLDL-triglyceride transport system, livers accumulate fat. Hepatic synthesis of fatty acids is reduced in compensation. Informational lacunae remain about genes affecting fat accumulation in liver, and the modulation of liver fat in the presence apoB truncation defects.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. R. Burnett, S. Zhong, Z. G. Jiang, A. J. Hooper, E. A. Fisher, R. S. McLeod, Y. Zhao, P. H. R. Barrett, R. A. Hegele, F. M. van Bockxmeer, et al.
Missense Mutations in APOB within the beta{alpha}1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia
J. Biol. Chem.,
August 17, 2007;
282(33):
24270 - 24283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Fasano, A. B. Cefalu, E. Di Leo, D. Noto, D. Pollaccia, L. Bocchi, V. Valenti, R. Bonardi, O. Guardamagna, M. Averna, et al.
A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2007;
27(3):
677 - 681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ikonen
Mechanisms for cellular cholesterol transport: defects and human disease.
Physiol Rev,
October 1, 2006;
86(4):
1237 - 1261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Parhofer and P. H. R. Barrett
Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies
J. Lipid Res.,
August 1, 2006;
47(8):
1620 - 1630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Clarke, A. J. Hooper, H. A. Headlam, J. H.Y. Wu, K. D. Croft, and J. R. Burnett
Assessment of Tocopherol Metabolism and Oxidative Stress in Familial Hypobetalipoproteinemia
Clin. Chem.,
July 1, 2006;
52(7):
1339 - 1345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Lin, P. Yue, Y. Xie, N. O. Davidson, N. Sakata, R. E. Ostlund Jr., Z. Chen, and G. Schonfeld
Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation
Am J Physiol Gastrointest Liver Physiol,
July 1, 2005;
289(1):
G146 - G152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Lin, P. Yue, Z. Chen, and G. Schonfeld
Hepatic triglyceride contents are genetically determined in mice: results of a strain survey
Am J Physiol Gastrointest Liver Physiol,
June 1, 2005;
288(6):
G1179 - G1189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Whitfield, P. H. R. Barrett, K. Robertson, M. F. Havlat, F. M. van Bockxmeer, and J. R. Burnett
Liver Dysfunction and Steatosis in Familial Hypobetalipoproteinemia
Clin. Chem.,
January 1, 2005;
51(1):
266 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Whitfield, P. H. R. Barrett, F. M. van Bockxmeer, and J. R. Burnett
Lipid Disorders and Mutations in the APOB Gene
Clin. Chem.,
October 1, 2004;
50(10):
1725 - 1732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Garbow, X. Lin, N. Sakata, Z. Chen, D. Koh, and G. Schonfeld
In vivo MRS measurement of liver lipid levels in mice
J. Lipid Res.,
July 1, 2004;
45(7):
1364 - 1371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Tanoli, P. Yue, D. Yablonskiy, and G. Schonfeld
Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity
J. Lipid Res.,
May 1, 2004;
45(5):
941 - 947.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|